ELUT Insider Trading

Insider Ownership Percentage: 40.80%
Insider Buying (Last 12 Months): $1,050,000.00
Insider Selling (Last 12 Months): $0.00

Elutia Insider Trading History Chart

This chart shows the insider buying and selling history at Elutia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$1.05Mbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Elutia Share Price & Price History

Current Price: $3.20
Price Change: Price Increase of +0.02 (0.63%)
As of 03/17/2025 05:00 PM ET

This chart shows the closing price history over time for ELUT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$3.20Closing price on 03/17/25:

SEC Filings (Institutional Ownership Changes) for Elutia (NASDAQ:ELUT)

74.03% of Elutia stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ELUT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.61Mbought$518ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
Elutia logo
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Read More on Elutia

Today's Range

Now: $3.20
Low: $3.12
High: $3.25

50 Day Range

MA: $3.04
Low: $2.55
High: $3.40

52 Week Range

Now: $3.20
Low: $2.28
High: $5.24

Volume

53,600 shs

Average Volume

45,137 shs

Market Capitalization

$110.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of Elutia?

Elutia's top insider investors include:
  1. Highcape Capital, LP (Director)
  2. Birchview Capital, Lp (Major Shareholder)
Learn More about top insider investors at Elutia.

Who are the major institutional investors of Elutia?

Elutia's top institutional shareholders include:
  1. AIGH Capital Management LLC — 8.90%
  2. Silverarc Capital Management LLC — 5.16%
  3. Birchview Capital LP — 3.55%
  4. Kennedy Capital Management LLC — 0.54%
  5. 683 Capital Management LLC — 0.23%
  6. Renaissance Technologies LLC — 0.17%
Learn More about top institutional investors of Elutia stock.

Which institutional investors are selling Elutia stock?

Within the previous quarter, ELUT stock was sold by these institutional investors:
  1. Birchview Capital LP
  2. Kennedy Capital Management LLC
  3. Renaissance Technologies LLC

Which institutional investors are buying Elutia stock?

Within the last quarter, ELUT stock was acquired by institutional investors including:
  1. AIGH Capital Management LLC
  2. Silverarc Capital Management LLC
  3. 683 Capital Management LLC
  4. Citadel Advisors LLC
  5. Millennium Management LLC
  6. Northern Trust Corp
During the previous year, these company insiders have bought Elutia stock:
  1. Highcape Capital, LP (Director)
  2. Birchview Capital, Lp (Major Shareholder)
Learn More investors buying Elutia stock.